Core Points - The article highlights the recognition of 100 individuals from the non-public economic sector as "Outstanding Builders of Socialism with Chinese Characteristics" to encourage and motivate private economic actors [1][2][3] - Among the honorees, 9 individuals are from the textile industry, showcasing the sector's contribution to the economy [2] - The recognition aims to inspire private economic individuals to uphold their ideals, maintain development focus, and contribute to national strategies [3] Summary by Categories Recognition and Awards - A total of 100 individuals have been awarded the title of "Outstanding Builders of Socialism with Chinese Characteristics" by various government departments [1][2] - The textile industry has 9 representatives among the honorees, indicating its significance in the non-public economic sector [2] Economic Contributions - Since the 18th National Congress, the non-public economy in China has achieved sustained, healthy, and high-quality development, contributing to growth stability, innovation promotion, employment increase, and improved living standards [2] - The article emphasizes the role of private economic individuals in implementing major policies and strategies set by the government [2][3] Future Outlook - The article expresses optimism about the future of the non-public economy, encouraging private economic individuals to learn from the honorees and actively participate in national development [3]

Summary of Key Points Core Viewpoint - The company has provided guarantees for its subsidiaries, which are essential for their operational financing and growth, while ensuring that these guarantees are within the approved limits and backed by counter-guarantees from the subsidiaries [1][2][3]. Group 1: Guarantee Overview - The company has provided a guarantee of RMB 107.80 million for its wholly-owned subsidiary, Tibet Nordicon Biopharmaceutical Sales Co., Ltd., and RMB 100 million for its controlling subsidiary, Tibet Nordicon Pharmaceutical Co., Ltd. [1][2] - The total actual guarantee balance provided by the company is RMB 218.80 million for the biopharmaceutical subsidiary and RMB 350 million for the pharmaceutical subsidiary as of the announcement date [1][2]. - Both subsidiaries have provided counter-guarantees to the company [1][2]. Group 2: Internal Decision-Making Process - The company held board meetings on March 13, 2025, and April 8, 2025, to approve the guarantee and credit limit proposals, allowing a total credit limit of up to RMB 1 billion for the year 2025 [2][3]. - The controlling subsidiary's credit limit is capped at RMB 800 million, with the company providing joint liability guarantees for all debts incurred within this limit [2][3]. Group 3: Financial Data of Subsidiaries - Tibet Nordicon Biopharmaceutical Sales Co., Ltd. has total assets of RMB 440.84 million, net assets of RMB 130.46 million, total liabilities of RMB 310.38 million, operating income of RMB 1.29 billion, and a net profit of RMB 67.12 million, with an asset-liability ratio of 70.41% [4]. - Tibet Nordicon Pharmaceutical Co., Ltd. has total assets of RMB 1.13 billion, net assets of RMB 672.72 million, total liabilities of RMB 452.93 million, operating income of RMB 1.37 billion, and a net profit of RMB 121.28 million, with an asset-liability ratio of 40.24% [5]. Group 4: Guarantee Agreement Details - The guarantee for Tibet Nordicon Biopharmaceutical Sales Co., Ltd. is with China Bank, with a limit of RMB 107.80 million, covering all principal, interest, penalties, and related costs for three years [5][6]. - The guarantee for Tibet Nordicon Pharmaceutical Co., Ltd. is with Citic Bank, with a limit of RMB 100 million, covering similar financial obligations for three years [5][6]. Group 5: Risk Management and Control - The company maintains effective control over the operational risks and decision-making of its subsidiaries, ensuring that the risks associated with the guarantees are manageable [6][7]. - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 800 million, with no overdue guarantees reported [7].

证券代码：600211 证券简称：西藏药业 公告编号：2025-022 西藏诺迪康药业股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：本公司全资子公司西藏诺迪康生物医药销售有限公司（以下简称"生 物医药"）及本公司控股子公司西藏诺迪康医药有限公司（以下简称"医药公司"）；本 次担保不存在关联担保。 ●本次担保金额及已实际为其提供的担保余额：近期我公司为生物医药提供担保金额 为人民币 10,780.29 万元；为医药公司提供担保金额为人民币 10,000 万元。截至本公告日， 我公司已实际为生物医药提供的担保余额为人民币 21,880.29 万元；为医药公司提供的担保 余额为人民币 35,000 万元。 ●本次担保是否有反担保：上述被担保公司向本公司提供反担保。 ●对外担保逾期的累计数量：无。 ●特别风险提示：本次被担保对象生物医药为资产负债率超过 70%的公司，敬请投资 者注意相关风险。 一、担保情况概述 （一）担保基本情况 根据公司生产经营及业 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-021 ●本次担保是否有反担保：被担保全资子公司生物医药向本公司提供反担保。 ●对外担保逾期的累计数量：无。 ●特别风险提示：本次被担保对象生物医药为资产负债率超过 70%的公司，敬请投资 者注意相关风险。 一、担保情况概述 （一）担保基本情况 西藏诺迪康药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：本公司全资子公司西藏诺迪康生物医药销售有限公司（以下简称"生 物医药"）；本次担保不存在关联担保。 ●本次担保金额及已实际为其提供的担保余额：近期我公司为生物医药提供担保金额 为人民币 4,100 万元。截至本公告日，我公司已实际为生物医药提供的担保余额为人民币 19,100 万元。 公司名称：西藏诺迪康生物医药销售有限公司 统一社会信用代码：91540091MABUYT4X4H 成立日期：2022-7-25 注册资本：2800 万元 具体内容详见公司于 2025 年 3 月 15 ...

Group 1 - China State Construction signed new contracts totaling 1.52 trillion yuan from January to April, representing a year-on-year increase of 2.8% [1] - Yongpu Medical's subsidiary obtained a medical device business license valid until May 7, 2030, allowing it to engage in medical device retail and wholesale [1] - Ningbo Maritime received a government subsidy of 4.42 million yuan, which will impact its net profit for the fiscal year 2025 [1] Group 2 - Mingpu Optoelectronics obtained a patent for a magnetic powder core and its preparation method, enhancing its capabilities in magnetic materials technology [1] - Digital Zhitong plans to establish a wholly-owned subsidiary in Beijing with a registered capital of 5 million yuan [1] - Zhongmin Energy's shareholder plans to reduce its stake by up to 0.28% of the company's total shares [1][6] Group 3 - Tunnel Holdings' controlling shareholder intends to increase its stake in the company by investing between 250 million to 500 million yuan [1] - China Telecom appointed Liu Guiqing as the new President and COO [1] - Datang Power completed the issuance of 3 billion yuan in medium-term notes, with proceeds aimed at repaying debt and supplementing working capital [1] Group 4 - *ST Weihai won a bid for a flood control project worth 182 million yuan, accounting for 7.35% of its audited revenue for 2024 [1] - Huijin Tong announced a cash dividend of 0.0868 yuan per share, totaling 29.44 million yuan [1] - Xinkai Energy's shareholders plan to reduce their holdings by a combined total of 4% of the company's shares [1][39] Group 5 - Xinhuan Group's subsidiary won a 1.02 billion yuan nuclear power project contract [1] - Southern Airlines reported a 12.14% year-on-year increase in passenger turnover for April [1] - Xinjiang Torch plans to acquire 100% equity of Yushan Litai for 125 million yuan [1]

证券代码：600211 证券简称：西藏药业 公告编号：2025-020 西藏诺迪康药业股份有限公司 关于全资子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司全资子公司成都诺迪康生物制药有限公司于近日收到国家药品监督管理局颁发的 《药品补充申请批准通知书》，现将相关情况公告如下： 一、《药品补充申请批准通知书》的主要内容 受理号：CYSB2300200 通知书编号：2025B02098 药品通用名称：注射用重组人脑利钠肽 商品名称：新活素 剂型：注射剂 包装规格：1 瓶/盒；2 瓶/盒 药品注册标准编号：YBS00272025 申请内容：药学研究信息：1、在原车间紧邻的综合空闲厂房内，按原产线的生产规模及 生产工艺复制了一条冻干生产线（冻干车间 B 线）；2、在质量部四楼新建生物活性实验室。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事 项符合药品注册的有关要求，批准本品如下补充申请事项：1、在原车间紧邻的综合空闲厂房 内，按原产线的生产规模及生产工艺 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 712,108,915.50, a slight increase of 1.12% compared to CNY 704,221,182.53 in the same period last year[3]. - Net profit attributable to shareholders decreased by 13.95% to CNY 269,280,367.86 from CNY 312,919,132.01 year-on-year[3]. - Basic and diluted earnings per share decreased by 13.40% to CNY 0.84 from CNY 0.97 in the same period last year[3]. - Total operating revenue for Q1 2025 was CNY 712,108,915.50, a slight increase of 1.26% compared to CNY 704,221,182.53 in Q1 2024[24]. - Net profit for Q1 2025 was CNY 270,248,719.59, representing a decrease of 14.26% from CNY 315,241,177.60 in Q1 2024[26]. - The company's total equity rose to CNY 4,136,289,317.66, up from CNY 3,952,105,109.53 in Q1 2024[21]. - The net profit for Q1 2025 was CNY 115,441,498.46, a decrease of 49.0% compared to CNY 226,765,743.82 in Q1 2024[38]. - Operating profit for Q1 2025 was CNY 127,258,587.32, down 48.9% from CNY 249,078,774.66 in the same period last year[38]. Cash Flow and Assets - The net cash flow from operating activities fell by 28.97% to CNY 309,809,945.57, down from CNY 436,177,775.81 in the previous year[3]. - Cash flow from operating activities for Q1 2025 showed a positive trend, indicating improved liquidity[27]. - Operating cash flow for the first quarter of 2025 was CNY 309,809,945.57, a decrease of 29% compared to CNY 436,177,775.81 in the same period of 2024[31]. - Total cash inflow from investment activities was CNY 1,056,215,668.24, while cash outflow was CNY 1,354,801,433.23, resulting in a net cash flow of -CNY 298,585,764.99, an improvement from -CNY 339,585,126.64 year-over-year[32]. - Cash and cash equivalents increased to CNY 1,921,176,666.70 from CNY 1,648,214,061.09, reflecting a rise of about 16.5%[19]. - The cash and cash equivalents at the end of the first quarter of 2025 were CNY 1,474,211,204.87, up from CNY 1,040,096,508.32 in the previous year[32]. - The net increase in cash and cash equivalents for the first quarter of 2025 was CNY 168,310,038.82, down from CNY 357,916,946.08 in the previous year[32]. Investments and R&D - The company invested RMB 300 million in Jiangsu Chentai Pharmaceutical Technology Co., holding a 13.04% stake, with the remaining 86.96% held by Alpha Biopharma (HK) Limited[10]. - R&D expenses increased significantly to CNY 5,275,211.59, up 80.66% from CNY 2,920,012.24 in Q1 2024[24]. - Research and development expenses increased to CNY 5,017,613.95 in Q1 2025, up 66.7% from CNY 3,009,897.33 in Q1 2024[38]. - The company is focused on expanding its market presence through strategic investments in innovative drug development[10]. - The company is committed to developing clinical urgently needed innovative therapeutic drugs[10]. Government Subsidies and Financial Position - The company received government subsidies amounting to CNY 13,814,838.25, which contributed to the net profit[5]. - The decrease in net profit was primarily due to a reduction in government subsidies received, which fell by CNY 75,727,300 compared to the previous year[5]. - The company has established a strong financial position with significant cash management and investment strategies in place[12]. Shareholder Information - The company reported a total of 49,164 common shareholders at the end of the reporting period[7]. Market and Product Development - The company has not provided any new product or technology development updates in the conference call[18]. - There were no announcements regarding market expansion or mergers and acquisitions during the call[18]. - The company did not issue any specific performance guidance for the upcoming quarters[18].

| 证券代码 | 证券简称 | 每10股派现（元） | 每10股送转（股） | 最新收盘价（元） | 近5日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 000823 | 超声电子 | 2.000 | - | 9.57 | 7.41 | | 002852 | 道道全 | 1.280 | - | 9.45 | 2.94 | | 300146 | 汤臣倍健 | 3.600 | - | 11.36 | 1.79 | | 002911 | 佛燃能源 | 2.300 | - | 10.92 | 1.58 | | 300750 | 宁德时代 | 45.530 | - | 225.46 | 0.65 | | 600211 | 西藏药业 | 7.280 | - | 36.85 | -0.11 | | 301389 | 隆扬电子 | 2.500 | - | 17.39 | -4.24 | 对于关注分红的投资者而言，在分红方案密集实施季，上市公司分红有两个比较重要的日期，即股权登 记日和除权除息日。以除权除息日计算，目前有30家公司分配方案已经实施，未来一段时间需要关注的 就是 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-019 | 股东名称 | 西藏华西药业集团有限公司 | | | | | --- | --- | --- | --- | --- | | 本次解质股份 | | 2,009 | 万股 | | | 占其所持股份比例 | | | 35.78% | | | 占公司总股本比例 | | | 6.23% | | | 解质完成时间 | 2025 年 | 4 月 | 14 | 日 | | 持股数量 | 5,614.83 | | 万股 | | | 持股比例 | | | 17.42% | | | 剩余被质押股份数量 | | | | 0 | | 剩余被质押股份数量占其所持股份比例 | | | | 0 | | 剩余被质押股份数量占公司总股本比例 | | | | 0 | 一、股份解质情况 本次解质股份用于以下质押，具体情况如下： 二、股份质押情况 西藏诺迪康药业股份有限公司 关于持股 5%以上的股东股份解质及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●西藏华 ...

证券简称：西藏药业 证券代码：600211 编号：2025-017 本公司于 2025 年 4 月 8 日在《中国证券报》《上海证券报》《证券时报》及上海证券交 易所网站（www.sse.com.cn）披露了《关于召开 2024 年年度业绩说明会的公告》。2025 年 4 月 15 日 15:00—16:00，公司董事长陈达彬先生、总经理郭远东先生、副总经理兼董秘刘 岚女士、财务总监陈俊先生、独立董事满加云先生、林建昆先生出席了本次业绩说明会， 并与投资者进行互动交流和沟通，就投资者关注的问题进行了回复。 二、投资者提出的问题及公司回复情况 公司就投资者在本次说明会上提出的所有问题给予了回答，问答整理如下： 关于 2024 年年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2025 年 4 月 15 日（星期二）15:00-16:00 在上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/），以网络文字互动方式召开了公司 2024 年年度 业绩说明 ...